Literature DB >> 15476092

Interferon beta-1a in chronic inflammatory demyelinating polyneuropathy: case report.

Andrés Maria Villa1, Orlando Garcea, Marianna Di Egidio, Roberto Saizar, Roberto Eduardo Pedro Sica.   

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated neuropathy. It presents with a course of progression which may be slow and steady or step-wise or relapsing. Sensory ataxic polyneuropathy may be the only clinical manifestation of this disease. Treatment with interferon beta1a (INF beta1a) has been tried with different results in patients who were refractory to other, more conventional, immunomodulatory therapies. Here we report on a patient who had a relapsing form of pure sensory ataxic CIDP and who failed to respond to intravenous human immunoglobulin. He was put on INF beta1a for 3 years. During this period he suffered no relapses while his condition stabilized.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15476092     DOI: 10.1590/s0004-282x2004000500031

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  3 in total

1.  Original Surgical Treatment and Long-term Follow-up for Chronic Inflammatory Demyelinating Polyradiculoneuropathy Causing a Compressive Cervical Myelopathy: Review of the Literature.

Authors:  Julien Rigal; Emanuele Quarto; Lisa Boue; Laurent Balabaud; Wendy Thompson; Thibault Cloché; Stephane Bourret; Jean Charles Le Huec
Journal:  Neurospine       Date:  2022-05-17

Review 2.  Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside.

Authors:  Amanda C Peltier; Peter D Donofrio
Journal:  Semin Neurol       Date:  2012-11-01       Impact factor: 3.420

Review 3.  Progress in Hematopoietic Stem Cell Transplantation for CIDP.

Authors:  Zhen Qin; Qianyi Huang; Jiangying Zou; Lisha Tang; Zhiping Hu; Xiangqi Tang
Journal:  Int J Med Sci       Date:  2020-01-14       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.